Best Telehealth GLP-1 Providers of 2026
GLP-1 receptor agonists have moved the entire weight-loss conversation. Telehealth opens access — but pricing, dosing flexibility, and the difference between brand-name and compounded formulations vary widely between providers. We evaluated 26 platforms that prescribe GLP-1s and ranked the ones that combine clinical oversight, formulary breadth, and transparent pricing.
Rankings combine clinical formulary depth, pricing transparency, and shipping reliability — weighted equally and reviewed quarterly. Read the full methodology →
The Ranking
Personalized clinical weight loss with state-licensed pharmacy fulfillment and an unusually low program entry price.
Flat-rate compounded GLP-1s plus brand-name Wegovy and Zepbound, with all dosages priced the same.
Broad-catalog telehealth covering hair, skin, weight loss, and sexual health, with free shipping and follow-ups bundled in.
Hormone optimisation platform with real biomarker testing and physician-guided protocols, for men and women.
Mainstream telehealth giant with FDA-approved GLP-1s, an insurance concierge, and prepay savings.
Affordable subscription telehealth with one of the largest compounded formularies in the industry.
Full-spectrum GLP-1 program with both compounded and brand-name access plus unlimited provider check-ins.
Flat upfront pricing with the same dose-equal cost across both compounded and brand-name GLP-1s.
Board-certified primary-care telehealth with the widest brand-name GLP-1 access in this list.
Asynchronous sexual and reproductive healthcare for women across every life stage.
Methodology
We scored each provider on four axes — formulary breadth (compounded plus brand-name access), pricing transparency, clinical oversight, and shipping reliability. The final ranking is the editor score that emerges from those four axes; nothing else.
What You Actually Need to Know Before Starting a Telehealth GLP-1
GLP-1 telehealth has gone from niche-clinic curiosity to mainstream weight-loss infrastructure in less than three years. The marketing has matured faster than the consumer literacy — most patients we hear from sign up not fully understanding the difference between Wegovy and a compounded semaglutide preparation, what a 503B pharmacy is, or how the FDA shortage list quietly determines whether the medication they're taking is even legal next quarter. The notes below are the briefing we'd give a friend before they signed up for any of the providers ranked above.
Compounded vs Brand-Name: The Distinction Most Pages Skip
When you sign up for a 'GLP-1 program' through telehealth, you are usually being prescribed one of two materially different products. The first is FDA-approved Wegovy or Zepbound — manufactured by Novo Nordisk and Eli Lilly respectively, with the same active ingredient and the same labeled dosing as the medication used in pivotal randomized trials. The second is compounded semaglutide or compounded tirzepatide, prepared by a state-licensed compounding pharmacy, not reviewed by the FDA for safety, efficacy, manufacturing quality, or labeling.
Compounded does not mean illegal. Under section 503A of the FD&C Act, traditional compounding pharmacies can prepare a copy of an FDA-approved drug only when that drug appears on the FDA's drug-shortage list. Throughout most of 2023 and 2024, both semaglutide and tirzepatide were on the list — making compounded versions broadly available through telehealth. Once the FDA removes a drug from the shortage list, the legal pathway for compounded copies narrows considerably. This means the compounded GLP-1 you start today may not be available the same way in six months. It is a real risk for a long-term protocol like weight management.
Practically, if you can afford brand-name Wegovy or Zepbound (with or without insurance), or if you have insurance that covers it, that is the cleaner pharmacological choice — same molecule, FDA oversight, predictable supply, predictable formulary. If cost rules out the brand-name pathway, compounded GLP-1s offered by clinics that disclose their pharmacy partner (ideally a 503B outsourcing facility) and provide a clear formulary statement are the next-best option. Clinics that obscure their compounding source or refuse to name a 503A vs 503B partner are an immediate yellow flag.
What the Trial Numbers Actually Mean
Wegovy's pivotal trial (STEP 1) showed a mean weight loss of 14.9% over 68 weeks at the 2.4 mg dose, versus 2.4% on placebo. Zepbound's pivotal trial (SURMOUNT-1) showed 20.9% over 72 weeks at the 15 mg dose, versus 3.1% on placebo. Both figures are remarkable — historically, lifestyle-only weight-loss programs produce 3-6% loss at 12 months, and pre-GLP-1 weight-loss medications produced 5-10%.
Two cautions about reading these numbers: first, both trials excluded participants with diabetes (a separate trial population) and titrated up to the maintenance dose over 16-20 weeks, which means your first three months on therapy will not look like the trial average. Second, the trials measured percent of body weight at week 68 or 72 against baseline — they did not measure five-year sustained loss. Real-world data is still emerging, but rebound after discontinuation is common, which is why most clinicians and our editorial position favor framing GLP-1 therapy as long-term metabolic medicine rather than a short-term weight-loss tool.
What Good Clinical Oversight Looks Like
GLP-1s are not benign drugs. The FDA labels carry warnings for pancreatitis, gallbladder disease, and (in animal models) thyroid C-cell tumors. The most common side effects — nausea, diarrhea, vomiting, constipation — are dose-dependent and usually titration-related, but they are not trivial: a patient titrating too quickly can lose meaningful weight from sheer GI distress, which is not the goal.
A telehealth clinic that does GLP-1 well will: (a) require a structured intake covering personal and family history of pancreatitis, thyroid cancer, and gallbladder disease; (b) titrate the dose on a defined schedule rather than letting the patient self-escalate; (c) make it easy to message a clinician when side effects appear, rather than gating support behind another consult fee; and (d) ask about adjacent medications — particularly for type 1 or insulin-using type 2 diabetics, where GLP-1s can cause hypoglycemia.
- Clinic does a structured medical history before prescribing, not just BMI screening
- Titration is provider-controlled, not patient-controlled
- Asynchronous messaging is unlimited and free, not gated behind extra consult fees
- The pharmacy partner is named (especially for compounded protocols)
- Refills require a brief check-in, not just a credit-card hit
The Real Monthly Cost
Headline pricing on a telehealth GLP-1 page is rarely the all-in monthly cost. Look for these line items: the program/membership fee, the medication fee at your maintenance dose (not your starting dose), shipping, lab work (some clinics require baseline labs), and any add-on charges for nutrition coaching or premium tiers. Compounded plans on flat-rate pricing avoid the dose-tier surprise; brand-name plans pass through the medication's published wholesale cost plus a markup.
For the 35+ providers in our directory, all-in monthly cost at the maintenance dose ranges from roughly $179/month (low-end compounded with no extras) to $1,400+/month (brand-name Wegovy or Zepbound at retail without insurance). The ranking above factors in this all-in cost, not the marketing-headline number.
If you take one thing away from this section: ask the clinic, before signing up, what the all-in monthly cost will be at your maintenance dose, where the medication is dispensed from, and how dose changes are handled. Any provider that hesitates on those three questions is not the right one — regardless of how aggressive the ad copy is.
What the Studies Actually Show
GLP-1 receptor agonists — semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) — are the active ingredients prescribed by every provider on this list. The figures below summarise the pivotal Phase 3 trials and the current FDA prescribing information.
| Endpoint | Finding |
|---|---|
| Mean weight loss (STEP 1, 68 weeks, 2.4 mg)1 | −14.9% body weight vs −2.4% placebo in adults with overweight/obesity without diabetes |
| Cardiovascular outcomes (SELECT, ~40 months)2 | 20% relative risk reduction in major adverse cardiovascular events (MACE) in adults with established CV disease and overweight/obesity |
| GI side effects (FDA prescribing information)3 | Nausea ≥10%, diarrhea ≥10%, vomiting ≥10%, constipation ≥10%; most cases mild–moderate and dose-dependent |
| Boxed warning3 | Risk of thyroid C-cell tumors observed in rodent studies; contraindicated in personal/family history of MTC or MEN 2 |
| Mean weight loss (SURMOUNT-1, 72 weeks, 15 mg)6 | −20.9% body weight vs −3.1% placebo in adults with obesity without diabetes |
| Mean weight loss with T2D (SURMOUNT-2, 72 weeks, 15 mg)7 | −14.7% body weight in adults with type 2 diabetes |
| Sleep apnea (SURMOUNT-OSA)8 | Tirzepatide reduced apnea-hypopnea index (AHI) by ~25–29 events/hour vs placebo at 52 weeks; FDA-approved labeling for moderate-to-severe OSA in obesity |
Frequently Asked Questions
What is the difference between compounded and brand-name GLP-1?
Compounded GLP-1s are mixed by licensed compounding pharmacies and are typically priced lower than brand-name. Brand-name GLP-1s such as Wegovy and Zepbound are FDA-approved finished products manufactured by Novo Nordisk and Eli Lilly. Both can be prescribed via telehealth.
Which telehealth providers prescribe brand-name Wegovy and Zepbound?
Within our list, TrimRx, MEDVi, Eden, GetThinMD, SkinnyRx, FuturHealth, JRNYS, PlushCare, and Ro all offer FDA-approved Wegovy and/or Zepbound through licensed clinicians.
Are compounded GLP-1s safe?
Compounded medications are legal when prescribed by a licensed clinician and dispensed by a state-licensed compounding pharmacy. Always verify the pharmacy's licensure and ask whether the active ingredient is sourced from an FDA-registered facility.
- STEP 1 — NEJM 2021 · Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989–1002.
- SELECT — NEJM 2023 · Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221–2232.
- FDA Prescribing Information — Wegovy (semaglutide) · WEGOVY (semaglutide) injection, for subcutaneous use. U.S. Food and Drug Administration prescribing information.
- SUSTAIN program — ADA scientific summary · Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 clinical trials. Diabetes Obes Metab 2019;21(7):1601–1613.
- FDA — Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (last updated 2024).
- SURMOUNT-1 — NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- SURMOUNT-2 — Lancet 2023 · Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402(10402):613–626.
- SURMOUNT-OSA — NEJM 2024 · Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193–1205.
- FDA Prescribing Information — Zepbound (tirzepatide) · ZEPBOUND (tirzepatide) injection, for subcutaneous use. U.S. Food and Drug Administration prescribing information.
- SURPASS — program summary · Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503–515.
- FDA — Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (last updated 2024).
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.
Which provider is right for you?
Three quick questions narrow 30+ GLP-1 telehealth providers down to one or two best fits.